Focal amplifications are associated with high grade and recurrences in stage Ta bladder carcinoma

Urinary bladder cancer is a heterogeneous disease with tumors ranging from papillary noninvasive (stage Ta) to solid muscle infiltrating tumors (stage T2+). The risk of progression and death for the most frequent diagnosed type, Ta, is low, but the high incidence of recurrences has a significant effect on the patients' quality of life and poses substantial costs for health care systems. Consequently, the purpose of this study was to search for predictive factors of recurrence on the basis of genetic profiling. A clinically well characterized cohort of Ta bladder carcinomas, selected by the presence or absence of recurrences, was evaluated by an integrated analysis of DNA copy number changes and gene expression (clone‐based 32K, respectively, U133Plus2.0 arrays). Only a few chromosomal aberrations have previously been defined in superficial bladder cancer. Surprisingly, the profiling of Ta tumors with a high‐resolution array showed that DNA copy alterations are relatively common in this tumor type. Furthermore, we observed an overrepresentation of focal amplifications within high‐grade and recurrent cases. Known (FGFR3, CCND1, MYC, MDM2) and novel candidate genes were identified within the loci. For example, MYBL2, a nuclear transcription factor involved in cell‐cycle progression; YWHAB, an antiapoptotic protein; and SDC4, an important component of focal adhesions represent interesting candidates detected within two amplicons on chromosome 20, for which DNA amplification correlated with transcript up‐regulation. The observed overrepresentation of amplicons within high‐grade and recurrent cases may be clinically useful for the identification of patients who will benefit from a more aggressive therapy.

[1]  Nidhi Sharma,et al.  E2f3a and E2f3b Contribute to the Control of Cell Proliferation and Mouse Development , 2008, Molecular and Cellular Biology.

[2]  M. DePamphilis,et al.  Contributions of the two accessory subunits, RNASEH2B and RNASEH2C, to the activity and properties of the human RNase H2 complex , 2008, Nucleic acids research.

[3]  Olivier Cussenot,et al.  Gene expression study of Aurora-A reveals implication during bladder carcinogenesis and increasing values in invasive urothelial cancer. , 2008, Urology.

[4]  D. Neal,et al.  High-Resolution Array-Based Comparative Genomic Hybridization of Bladder Cancers Identifies Mouse Double Minute 4 (MDM4) as an Amplification Target Exclusive of MDM2 and TP53 , 2008, Clinical Cancer Research.

[5]  Huan Yang,et al.  Identification of Aurora-A as a Direct Target of E2F3 during G2/M Cell Cycle Progression* , 2008, Journal of Biological Chemistry.

[6]  J. Komorowski,et al.  Profiling of copy number variations (CNVs) in healthy individuals from three ethnic groups using a human genome 32 K BAC‐clone‐based array , 2008, Human mutation.

[7]  Jan Komorowski,et al.  A segmental maximum a posteriori approach to genome-wide copy number profiling , 2008, Bioinform..

[8]  Takaaki Ito,et al.  Quantitative analysis of survivin mRNA expression in bladder transitional cell carcinomas. , 2008, Hinyokika kiyo. Acta urologica Japonica.

[9]  J. Davis Bioinformatics and Computational Biology Solutions Using R and Bioconductor , 2007 .

[10]  Ram H Datar,et al.  Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  D. Albertson,et al.  Gene amplification in cancer. , 2006, Trends in genetics : TIG.

[12]  Ola Spjuth,et al.  The LCB Data Warehouse , 2006, Bioinform..

[13]  P. Carroll,et al.  Bladder cancer stage and outcome by array-based comparative genomic hybridization. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  J. Taylor‐Papadimitriou,et al.  The ST6GalNAc-I Sialyltransferase Localizes throughout the Golgi and Is Responsible for the Synthesis of the Tumor-associated Sialyl-Tn O-Glycan in Human Breast Cancer* , 2006, Journal of Biological Chemistry.

[15]  J. Adolfsson,et al.  Prognostic significance of homozygous deletions and multiple duplications at the CDKN2A (p16INK4a)/ARF (p14ARF) locus in urinary bladder cancer , 2006, Scandinavian journal of urology and nephrology.

[16]  J. Ferlay,et al.  Cancer incidence and mortality in Europe, 2004. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  T. H. van der Kwast,et al.  FGFR3 and P53 Characterize Alternative Genetic Pathways in the Pathogenesis of Urothelial Cell Carcinoma , 2004, Cancer Research.

[18]  Gordon K Smyth,et al.  Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2004, Statistical applications in genetics and molecular biology.

[19]  Patrick G Buckley,et al.  Genomic microarrays in the spotlight. , 2004, Trends in genetics : TIG.

[20]  Robert Maurer,et al.  High‐throughput tissue microarray analysis of 11q13 gene amplification (CCND1, FGF3, FGF4, EMS1) in urinary bladder cancer , 2003, The Journal of pathology.

[21]  H. Wallerand,et al.  FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. , 2003, Cancer research.

[22]  M. Knowles,et al.  Mutation spectrum of the 9q34 tuberous sclerosis gene TSC1 in transitional cell carcinoma of the bladder. , 2003, Cancer research.

[23]  K. Rieger-Christ,et al.  Rieger‐Christ KM, Mourtzinos A, Lee PJ, et al. Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumor detection. Cancer. (2003) 98(4):737–44. , 2003 .

[24]  K. Rieger-Christ,et al.  Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumor detection , 2003, Cancer.

[25]  Brad T. Sherman,et al.  DAVID: Database for Annotation, Visualization, and Integrated Discovery , 2003, Genome Biology.

[26]  Wen-Lin Kuo,et al.  Array-based comparative genomic hybridization for genome-wide screening of DNA copy number in bladder tumors. , 2003, Cancer research.

[27]  F. Rousseau,et al.  Alteration of the PATCHED locus in superficial bladder cancer , 2003, Oncogene.

[28]  Rafael A Irizarry,et al.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.

[29]  Gunnar Steineck,et al.  Bladder Neoplasms--Regions at Chromosome 9 with Putative Tumour Suppressor Genes , 2003, Scandinavian journal of urology and nephrology.

[30]  D. Pinkel,et al.  A full-coverage, high-resolution human chromosome 22 genomic microarray for clinical and research applications. , 2002, Human molecular genetics.

[31]  M. Fukushima,et al.  Prognostic significance of thymidine kinase activity in bladder carcinoma , 2002, Cancer.

[32]  H. Moch,et al.  Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer , 2002, Oncogene.

[33]  S. Dudoit,et al.  Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. , 2002, Nucleic acids research.

[34]  T. H. van der Kwast,et al.  The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. , 2001, Cancer research.

[35]  C. Li,et al.  Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[36]  T. Koshikawa,et al.  Immunohistochemical demonstration of cyclin D1 in bladder cancers as an inverse indicator of invasiveness but not an independent prognostic factor , 2000, International journal of urology : official journal of the Japanese Urological Association.

[37]  Y. Ikehara,et al.  Cloning and expression of a human gene encoding an N-acetylgalactosamine-alpha2,6-sialyltransferase (ST6GalNAc I): a candidate for synthesis of cancer-associated sialyl-Tn antigens. , 1999, Glycobiology.

[38]  M. Knowles,et al.  Homozygous deletion at the 9q32–33 candidate tumor suppressor locus in primary human bladder cancer , 1999, Genes, chromosomes & cancer.

[39]  H. Moch,et al.  Chromosomal imbalances in noninvasive papillary bladder neoplasms (pTa). , 1999, Cancer research.

[40]  H. Grossman,et al.  Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer , 1999, Oncogene.

[41]  J. Tomaszewski,et al.  PTCH gene mutations in invasive transitional cell carcinoma of the bladder , 1998, Oncogene.

[42]  Patricia A. Elder,et al.  Structure and methylation-based silencing of a gene (DBCCR1) within a candidate bladder cancer tumor suppressor region at 9q32-q33. , 1998, Genomics.

[43]  E. Schuuring,et al.  Expression of cyclin D1 and EMS1 in bladder tumours; relationship with chromosome 11q13 amplification. , 1996, Oncogene.

[44]  S. Devries,et al.  Identification of gains and losses of DNA sequences in primary bladder cancer by comparative genomic hybridization , 1995, Genes, chromosomes & cancer.

[45]  J. Sherley,et al.  Regulation of human thymidine kinase during the cell cycle. , 1988, The Journal of biological chemistry.

[46]  E. Zwarthoff,et al.  Fibroblast growth factor receptor 3 mutations in bladder tumors correlate with low frequency of chromosome alterations. , 2008, Neoplasia.

[47]  D. Dobrota,et al.  Gene polymorphisms in bladder cancer. , 2008, Urologic oncology.

[48]  Peter Boyle,et al.  Cancer incidence and mortality in Europe , 2005, Sozial- und Präventivmedizin.

[49]  Gordon K. Smyth,et al.  limma: Linear Models for Microarray Data , 2005 .

[50]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[51]  T. Ørntoft,et al.  Nuclear volume and expression of T‐antigen, sialosyl‐Tn‐antigen, and Tn‐antigen in carcinoma of the human bladder. Relation to tumor recurrence and progression , 1992, Cancer.

[52]  B. Norlén,et al.  A grading system for the immunostaining of A, B and H blood group isoantigens in bladder carcinoma. , 1988, Anticancer research.